Laura K Barger1, Erin E Flynn-Evans2, Alan Kubey3, Lorcan Walsh3, Joseph M Ronda2, Wei Wang2, Kenneth P Wright4, Charles A Czeisler2. 1. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: lkbarger@hms.harvard.edu. 2. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA. 3. Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA. 4. Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA.
Abstract
BACKGROUND: Sleep deprivation and fatigue are common subjective complaints among astronauts. Previous studies of sleep and hypnotic drug use in space have been limited to post-flight subjective survey data or in-flight objective data collection from a small number of crew members. We aimed to characterise representative sleep patterns of astronauts on both short-duration and long-duration spaceflight missions. METHODS: For this observational study, we recruited crew members assigned to Space Transportation System shuttle flights with in-flight experiments between July 12, 2001, and July 21, 2011, or assigned to International Space Station (ISS) expeditions between Sept 18, 2006, and March 16, 2011. We assessed sleep-wake timing objectively via wrist actigraphy, and subjective sleep characteristics and hypnotic drug use via daily logs, in-flight and during Earth-based data-collection intervals: for 2 weeks scheduled about 3 months before launch, 11 days before launch until launch day, and for 7 days upon return to Earth. FINDINGS: We collected data from 64 astronauts on 80 space shuttle missions (26 flights, 1063 in-flight days) and 21 astronauts on 13 ISS missions (3248 in-flight days), with ground-based data from all astronauts (4014 days). Crew members attempted and obtained significantly less sleep per night as estimated by actigraphy during space shuttle missions (7·35 h [SD 0·47] attempted, 5·96 h [0·56] obtained), in the 11 days before spaceflight (7·35 h [0·51], 6·04 h [0·72]), and about 3 months before spaceflight (7·40 h [0·59], 6·29 h [0·67]) compared with the first week post-mission (8·01 h [0·78], 6·74 h [0·91]; p<0·0001 for both measures). Crew members on ISS missions obtained significantly less sleep during spaceflight (6·09 h [0·67]), in the 11 days before spaceflight (5·86 h [0·94]), and during the 2-week interval scheduled about 3 months before spaceflight (6·41 h [SD 0·65]) compared with in the first week post-mission (6·95 h [1·04]; p<0·0001). 61 (78%) of 78 shuttle-mission crew members reported taking a dose of sleep-promoting drug on 500 (52%) of 963 nights; 12 (75%) of 16 ISS crew members reported using sleep-promoting drugs. INTERPRETATION: Sleep deficiency in astronauts was prevalent not only during space shuttle and ISS missions, but also throughout a 3 month preflight training interval. Despite chronic sleep curtailment, use of sleep-promoting drugs was pervasive during spaceflight. Because chronic sleep loss leads to performance decrements, our findings emphasise the need for development of effective countermeasures to promote sleep. FUNDING: The National Aeronautics and Space Administration.
BACKGROUND:Sleep deprivation and fatigue are common subjective complaints among astronauts. Previous studies of sleep and hypnotic drug use in space have been limited to post-flight subjective survey data or in-flight objective data collection from a small number of crew members. We aimed to characterise representative sleep patterns of astronauts on both short-duration and long-duration spaceflight missions. METHODS: For this observational study, we recruited crew members assigned to Space Transportation System shuttle flights with in-flight experiments between July 12, 2001, and July 21, 2011, or assigned to International Space Station (ISS) expeditions between Sept 18, 2006, and March 16, 2011. We assessed sleep-wake timing objectively via wrist actigraphy, and subjective sleep characteristics and hypnotic drug use via daily logs, in-flight and during Earth-based data-collection intervals: for 2 weeks scheduled about 3 months before launch, 11 days before launch until launch day, and for 7 days upon return to Earth. FINDINGS: We collected data from 64 astronauts on 80 space shuttle missions (26 flights, 1063 in-flight days) and 21 astronauts on 13 ISS missions (3248 in-flight days), with ground-based data from all astronauts (4014 days). Crew members attempted and obtained significantly less sleep per night as estimated by actigraphy during space shuttle missions (7·35 h [SD 0·47] attempted, 5·96 h [0·56] obtained), in the 11 days before spaceflight (7·35 h [0·51], 6·04 h [0·72]), and about 3 months before spaceflight (7·40 h [0·59], 6·29 h [0·67]) compared with the first week post-mission (8·01 h [0·78], 6·74 h [0·91]; p<0·0001 for both measures). Crew members on ISS missions obtained significantly less sleep during spaceflight (6·09 h [0·67]), in the 11 days before spaceflight (5·86 h [0·94]), and during the 2-week interval scheduled about 3 months before spaceflight (6·41 h [SD 0·65]) compared with in the first week post-mission (6·95 h [1·04]; p<0·0001). 61 (78%) of 78 shuttle-mission crew members reported taking a dose of sleep-promoting drug on 500 (52%) of 963 nights; 12 (75%) of 16 ISS crew members reported using sleep-promoting drugs. INTERPRETATION:Sleep deficiency in astronauts was prevalent not only during space shuttle and ISS missions, but also throughout a 3 month preflight training interval. Despite chronic sleep curtailment, use of sleep-promoting drugs was pervasive during spaceflight. Because chronic sleep loss leads to performance decrements, our findings emphasise the need for development of effective countermeasures to promote sleep. FUNDING: The National Aeronautics and Space Administration.
Authors: D J Dijk; D F Neri; J K Wyatt; J M Ronda; E Riel; A Ritz-De Cecco; R J Hughes; A R Elliott; G K Prisk; J B West; C A Czeisler Journal: Am J Physiol Regul Integr Comp Physiol Date: 2001-11 Impact factor: 3.619
Authors: Steven W Lockley; John W Cronin; Erin E Evans; Brian E Cade; Clark J Lee; Christopher P Landrigan; Jeffrey M Rothschild; Joel T Katz; Craig M Lilly; Peter H Stone; Daniel Aeschbach; Charles A Czeisler Journal: N Engl J Med Date: 2004-10-28 Impact factor: 91.245
Authors: Christopher P Landrigan; Jeffrey M Rothschild; John W Cronin; Rainu Kaushal; Elisabeth Burdick; Joel T Katz; Craig M Lilly; Peter H Stone; Steven W Lockley; David W Bates; Charles A Czeisler Journal: N Engl J Med Date: 2004-10-28 Impact factor: 91.245
Authors: Mathias Basner; Tyler M Moore; Emanuel Hermosillo; Jad Nasrini; David F Dinges; Ruben C Gur; Bernd Johannes Journal: Aerosp Med Hum Perform Date: 2020-11-01 Impact factor: 1.053
Authors: Dorothee Fischer; Andrew W McHill; Akane Sano; Rosalind W Picard; Laura K Barger; Charles A Czeisler; Elizabeth B Klerman; Andrew J K Phillips Journal: Sleep Date: 2020-06-15 Impact factor: 5.849
Authors: Andrew W McHill; Andrew Jk Phillips; Charles A Czeisler; Leigh Keating; Karen Yee; Laura K Barger; Marta Garaulet; Frank Ajl Scheer; Elizabeth B Klerman Journal: Am J Clin Nutr Date: 2017-09-06 Impact factor: 7.045
Authors: Matthew D Regan; Erin E Flynn-Evans; Yuri V Griko; Thomas S Kilduff; Jon C Rittenberger; Keith J Ruskin; C Loren Buck Journal: J Appl Physiol (1985) Date: 2020-01-30
Authors: Saurabh S Thosar; Alec M Berman; Maya X Herzig; Sally A Roberts; Michael R Lasarev; Steven A Shea Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-08-08 Impact factor: 3.619
Authors: Mathias Basner; Adam Savitt; Tyler M Moore; Allison M Port; Sarah McGuire; Adrian J Ecker; Jad Nasrini; Daniel J Mollicone; Christopher M Mott; Thom McCann; David F Dinges; Ruben C Gur Journal: Aerosp Med Hum Perform Date: 2015-11 Impact factor: 1.053